Novo Nordisk touts expansion in Boston, cuts about 100 jobs in two other US cities
Novo Nordisk is expanding its R&D and lab-based activities in Boston while adding jobs — and cutting some elsewhere, too.
The company announced today it’s adding more than 200 new jobs, with about 150 of them focused on data science, biology or chemistry research and ribonucleic acid interference (RNAi) R&D in Lexington, Cambridge and Watertown, MA.
But now that Boston will be the “principal” R&D site in the US, about 20 positions in Indianapolis and 80 positions in Seattle will be cut as lab-based work in Seattle is moved to other locations globally and closer to the R&D facility in Indianapolis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters